» start page

 » tutorial / help

 » documentation
    
publications
    
about / tech info

 » personal annotations
    
load /save

 » quiz mode

 » authors / contact

 » Contents listing
    
short long WHO

  Normal breast
  Non-neoplastic lesions
  Benign epithelial
   proliferations
  Fibro/myoepithelial
   tumors

  Tumors of the nipple

  Lobular neoplasia

  Intraductal prolifera-
   tive lesions

  Invasive epithelial
   tumors

    
IDC ILC Other

  Mesenchymal tumors

  Hematopoetic and
   metastatic tumors

  IH-stainings, TMAs,
   FISH and CISH

Welcome
The present virtual microscopy atlas currently features more than 150 digitized slides accompanied by concise descrip-
tions. The atlas follows the recently published WHO classifica-
tion of tumors of the breast (IARC Press, 2003).     More info

News:
FISH and CISH samples added to the IH section
Atlas described in December issue of Journal of
Clinical Pathology, with accompanying Editorial (full-text pdfs available).
New view interface released, including contr & brightness          adjustment.

Before you start
The virtual slides can be viewed on a standa
rd Windows PC with MS Internet Explorer or FireFox. Mac and Linux support will be added in the near future.

If you are a first-time visitor, get concise information on the requirements and usage of the WebMicroscope by clicking through the 7-step Quickstart tutorial.
Contents
Click a main category in the margin, or view a complete contents listing.

Quiz mode
View slides as unknown and test your skills in assessing the diagnosis.

Annotations
Make your personal set of annotations and share findings with colleagues
Research centers
Institute of Medical Technology, University of Tampere, Finland
Biomedical Informatics Group, HUCH Clinical Research Institute,
Helsinki, Finland.

Centre for Laboratory Medicine, TAYS, Tampere, Finland.                  More info


All material on this website is protected by copyright. By accessing or downloading contents
from this website, you expressly agree and consent to our terms and conditions.